The APHL Molecular Subcommittee provides guidance on Frequently Asked Questions related to molecular testing. Click on the questions listed under the headers below to view answers to the FAQ.

Considerations in Changing the Molecular Testing Platform or Assay for Cystic Fibrosis Screening (click questions to expand)

  1. What are the expectations of CF NBS in your state?

  2. What are the genotypes of people in your state with a diagnosis of CF (or CRMS or CFRD, dependent on your answers to question 1)?

  3. Are there people with genotypes of CF (or CRMS or CFRD) who would NOT be identified by your current testing algorithm and panel?

  4. Are there people with genotypes of CF (or CRMS or CFRD) who would NOT be identified by your newly proposed testing algorithm and panel?

  5. Have you inquired with your NBS follow-up program regarding the algorithm used to follow infants who screen positive with the proposed laboratory algorithm changes?

  6. What babies will you miss?

  7. Laboratory factors to consider when selecting a new molecular testing platform/assay: